Showing 1,261 - 1,280 results of 1,447 for search '"liver disease"', query time: 0.07s Refine Results
  1. 1261
  2. 1262

    Development and validation of a machine learning-based model to predict survival in patients with cirrhosis after transjugular intrahepatic portosystemic shuntResearch in context by Binlin Da, Huan Chen, Wei Wu, Wuhua Guo, Anru Zhou, Qin Yin, Jun Gao, Junhui Chen, Jiangqiang Xiao, Lei Wang, Ming Zhang, Yuzheng Zhuge, Feng Zhang

    Published 2025-01-01
    “…The RF model outperformed other scoring systems, such as the (Child-Turcotte-Pugh score) CTP, (model for end-stage liver disease) MELD, (sodium MELD) MELD-Na, (Freiburg index of post-TIPS survival) FIPS and (Albumin-Bilirubin) ALBI, showing the highest (area under the curve) AUC of 0.82 (95% CI: 0.72, 0.91) and 0.7 (95% CI: 0.60, 0.79) in predicting 1-year survival across the testing set and external validation cohort. …”
    Get full text
    Article
  3. 1263
  4. 1264

    Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver Injury by Guanting Li, Yourong Hu, Han Zhao, Ziyu Peng, Xin Shang, Jia Zhang, Kunxin Xie, Meiwei Li, Xiaohang Zhou, Qinyao Zhou, Kai Li, Fang Zhou, Heyao Wang, Zhijian Xu, Jiali Liu, Peng Sun

    Published 2025-01-01
    “…Abstract Obesity and nonalcoholic fatty liver disease (NAFLD) are established risk factors for drug‐induced liver injury (DILI). …”
    Get full text
    Article
  5. 1265

    A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma by Torsten Diesinger, Alfred Lautwein, Sebastian Bergler, Dominik Buckert, Christian Renz, Radovan Dvorsky, Vyacheslav Buko, Siarhei Kirko, Edith Schneider, Florian Kuchenbauer, Mukesh Kumar, Cagatay Günes, Felicitas Genze, Berthold Büchele, Thomas Simmet, Martin Haslbeck, Kai Masur, Thomas Barth, Dieter Müller-Enoch, Thomas Wirth, Thomas Haehner

    Published 2021-01-01
    “…Cytochrome P450 2E1 (CYP2E1) is a key target protein in the development of alcoholic and nonalcoholic fatty liver disease (FLD). The pathophysiological correlate is the massive production of reactive oxygen species. …”
    Get full text
    Article
  6. 1266

    Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet by Lakshmi Arivazhagan, Sofie Delbare, Robin A. Wilson, Michaele B. Manigrasso, Boyan Zhou, Henry H. Ruiz, Kaamashri Mangar, Ryoko Higa, Emily Brown, Huilin Li, Michael J. Garabedian, Ravichandran Ramasamy, Kathryn J. Moore, Edward A. Fisher, Neil D. Theise, Ann Marie Schmidt

    Published 2025-02-01
    “…Background & Aims: Metabolic syndrome-associated steatotic liver disease (MASLD) and metabolic syndrome-associated steatohepatitis (MASH) have global prevalence rates exceeding 25% and 3-6%, respectively. …”
    Get full text
    Article
  7. 1267

    Placental growth factor modulates endothelial NO production and exacerbates experimental hepatopulmonary syndrome by Fabien Robert, Feriel Benchenouf, My Ngoc Ha, Alessandra Cuomo, Mina Ottaviani, Maxime Surbier, Raphaël Thuillet, Corinne Normand, Florent Dumont, Céline Verstuyft, Frederic Fiore, Frederic Guinut, Marc Humbert, Audrey Coilly, Emmanuel Gonzales, Olivier Sitbon, Ly Tu, Christophe Guignabert, Laurent Savale

    Published 2025-03-01
    “…Methods: Circulating PlGF levels were measured in 64 controls and 137 patients with liver disease, with or without HPS. Two rat models, common bile duct ligation (CBDL) and long-term partial portal vein ligation (PPVL), were used. …”
    Get full text
    Article
  8. 1268
  9. 1269
  10. 1270
  11. 1271
  12. 1272
  13. 1273
  14. 1274
  15. 1275
  16. 1276
  17. 1277
  18. 1278
  19. 1279
  20. 1280